GLAGOV Imaging Study Of Amgen's Repatha Bodes Well For PCSK9 Class
Positive results in GLAGOV lift PCSK9 inhibitor Repatha, but most likely are still not enough to get rid of reimbursement restrictions for the class, analysts say.
Positive results in GLAGOV lift PCSK9 inhibitor Repatha, but most likely are still not enough to get rid of reimbursement restrictions for the class, analysts say.